WILL-EMI NISNCT06883240
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
At risk: Primary completion moved at least 2 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 17 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary and study completion pushed from Nov 1, 2026 to Jan 18, 2027
- Study sites: 26 to 25
- Minor Study sites: 27 to 26v21
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Enrollment increased: 40 → 44 participants
- Site details revised at 27 of 27 sites
- Minor Site details revised at 2 of 27 sitesv19
- Minor Site details revised at 3 of 27 sitesv18
Show 11 earlier versionsHide 11 earlier versions
- Minor Site details revised at 1 of 27 sitesv14
- Minor Study sites: 26 to 27v13
- Minor Study sites: 25 to 26v12
- Minor Study sites: 23 to 25v11
- Minor Study sites: 20 to 23v9
- Minor Study sites: 18 to 20v8
- Minor Study sites: 13 to 18v7
- Minor Study sites: 8 to 13v6
- Minor Start date changed from estimate of May 27, 2025 to Apr 29, 2025v5
- Minor Study sites: 4 to 8v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 14, 2025 to May 27, 2025
- Study sites: 0 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Participants with Type 3 VWD, aged 2 years and above, who are currently on standard of care (SOC) prophylactic therapy are anticipated to remain on the chosen SOC regimen during the study. Dosing and treatment duration of any studied medicinal products collected as part of this study are at the discretion of the treating physician in accordance with local labeling or local treatment guidelines.
Drugs: Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
Sites
25 sites in 13 countries
Germany 3, Italy 3, United Kingdom 3, United States 3, Canada 2, France 2, Japan 2, Spain 2, Belgium 1, Colombia 1, Netherlands 1, Poland 1, Sweden 1